Qyuns Therapeutics (HKG:2509) has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally under an out-license agreement, a Thursday Hong Kong bourse filing said.

The biotechnology company will receive a one-time upfront payment of $10 million under the contract, as well as around 24.88% equity interest in Caldera Therapeutics.

The firm may also receive additional milestone payments of up to $545 million and tiered royalties.

QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders.